These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32537333)

  • 21. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
    Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
    Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects.
    Harii K; Kawashima M; Furuyama N; Lei X; Hopfinger R; Lee E
    Aesthetic Plast Surg; 2017 Oct; 41(5):1186-1197. PubMed ID: 28733805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
    Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines.
    Joseph JH; Maas C; Palm MD; Lain E; Glaser DA; Bruce S; Yoelin S; Cox SE; Fagien S; Sangha S; Maltman J; Lei X; Brin MF
    Aesthet Surg J; 2022 Oct; 42(11):1318-1327. PubMed ID: 35704394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of OnabotulinumtoxinA treatment for crow's feet lines on patient-reported outcomes.
    Dayan S; Coleman WP; Dover JS; De Boulle K; Street J; Romagnano L; Daniels S; Kowalski JW; Lei X; Lee E
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S67-74. PubMed ID: 25548848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial.
    Carruthers A; Bruce S; de Coninck A; Connolly S; Cox SE; Davis PG; Campo A; Lei X; Somogyi C; Lee E; McLean H; Beddingfield F
    Dermatol Surg; 2014 Nov; 40(11):1181-90. PubMed ID: 25347451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient-reported Outcomes in Chinese Subjects Treated with OnabotulinumtoxinA for Crow's Feet Lines.
    Wu Y; Li C; Garcia J; Baradaran S
    J Clin Aesthet Dermatol; 2021 Oct; 14(10):27-31. PubMed ID: 34976286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Safety And Effectiveness Of OnabotulinumtoxinA Treatment Of Crow's Feet Lines And Glabellar Lines: Results Of A Korean Postmarketing Surveillance Study.
    Yi DJ; Hwang S; Son J; Yushmanova I; Anson Spenta K; St Rose S
    Clin Cosmet Investig Dermatol; 2019; 12():851-856. PubMed ID: 31819582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lifting effect of onabotulinumtoxinA in patients treated for glabellar and crow's feet rhytids.
    Norman S
    J Cosmet Laser Ther; 2020 Nov; 22(6-8):232-238. PubMed ID: 33944656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective rater- and subject-blinded study comparing the efficacy of incobotulinumtoxinA and onabotulinumtoxinA to treat crow's feet: a clinical crossover evaluation.
    Muti G; Harrington L
    Dermatol Surg; 2015 Jan; 41 Suppl 1():S39-46. PubMed ID: 25548844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.
    Kassir R; Kolluru A; Kassir M
    Dermatol Ther (Heidelb); 2013 Dec; 3(2):179-89. PubMed ID: 24318416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Full-face treatment with onabotulinumtoxinA: Results from a single-center study.
    D'Emilio R; Rosati G
    J Cosmet Dermatol; 2020 Apr; 19(4):809-816. PubMed ID: 31486568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OnabotulinumtoxinA versus PrabotulinumtoxinA-xvfs: A Randomized, Triple-blind, Split-face Study on the Time to Onset, Rhytid Appearance, and Patient Satisfaction in Forehead and Glabellar Lines.
    Vasile G; Green C; Bhatti H; Ilyas M; Buckley C; Saleeby E; Weiss E
    J Clin Aesthet Dermatol; 2023 May; 16(5):47-49. PubMed ID: 37288279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet Lines.
    Han HS; Yoo KH; Lee JS; Huh CH; Kwon SH; Lee YW; Kim BJ
    Dermatol Surg; 2021 Apr; 47(4):e127-e131. PubMed ID: 33795571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
    Ascher B; Rzany BJ; Grover R
    Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose for the treatment of moderate to severe glabellar lines.
    Dayan S; Joseph J; Moradi A; Lorenc ZP; Coleman K; Ablon G; Kaufman-Janette J; Cox SE; Campbell A; Munavalli G; Prygova I
    J Cosmet Dermatol; 2022 Jun; 21(6):2407-2416. PubMed ID: 35266281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
    Cheon HI; Jung N; Won CH; Kim BJ; Lee YW
    Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles.
    Yeilding RH; Fezza JP
    Plast Reconstr Surg; 2015 May; 135(5):1328-1335. PubMed ID: 25919246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
    Baumann L; Dayan S; Connolly S; Silverberg N; Lei X; Drinkwater A; Gallagher CJ
    Dermatol Surg; 2016 May; 42(5):598-607. PubMed ID: 27110893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.